Search Results - "Swift, Regina A"

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients by Ghermezi, Michael, Li, Mingjie, Vardanyan, Suzie, Harutyunyan, Nika Manik, Gottlieb, Jillian, Berenson, Ariana, Spektor, Tanya M, Andreu-Vieyra, Claudia, Petraki, Sophia, Sanchez, Eric, Udd, Kyle, Wang, Cathy S, Swift, Regina A, Chen, Haiming, Berenson, James R

“…B-cell maturation antigen is expressed on plasma cells. In this study, we have identified serum B-cell maturation antigen as a novel biomarker that can monitor…”
Get full text

A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma by BERENSON, James R, MATOUS, Jeffrey, SWIFT, Regina A, MAPES, Russell, MORRISON, Blake, YEH, Howard S

“…Purpose: This multicenter, open-label, phase I/II dose escalation study assessed the safety/tolerability and initial efficacy of arsenic…”
Get full text

Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss by BERENSON, James R, YELLIN, Ori, SWIFT, Regina A, BOCCIA, Ralph V, FLAM, Marshall, WONG, Siu-Fun, BATUMAN, Olcay, MOEZI, Mehdi M, WOYTOWITZ, Donald, DUVIVIER, Herbert, NASSIR, Youram

“…Purpose: Patients with monoclonal gammopathy of undetermined significance (MGUS) have increased rates of bone resorption, osteopenia, osteoporosis, and risk of…”
Get full text

A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma by Berenson, James R, Yellin, Ori, Patel, Ravi, Duvivier, Herb, Nassir, Youram, Mapes, Russell, Abaya, Christina DiLauro, Swift, Regina A

“…Purpose: This open-label, phase I dose-escalation study assessed the safety, tolerability, and initial efficacy of Samariam 153 ( 153 Sm)-lexidronam/bortezomib…”
Get full text

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival by Sanchez, Eric, Li, Mingjie, Kitto, Alex, Li, Jennifer, Wang, Cathy S., Kirk, Dylan T., Yellin, Ori, Nichols, Cydney M., Dreyer, Marissa P., Ahles, Cameryn P., Robinson, Austin, Madden, Erik, Waterman, Gabriel N., Swift, Regina A., Bonavida, Benjamin, Boccia, Ralph, Vescio, Robert A., Crowley, John, Chen, Haiming, Berenson, James R.

“…Summary Although TNFRSF17 (also designated as B‐cell maturation antigen (BCMA)) is expressed on tumour cells in B‐cell malignancies, it has not been found in…”
Get full text

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma by Berenson, James R, To, Jennifer, Spektor, Tanya M, Martinez, Daisy, Turner, Carley, Sanchez, Armando, Ghermezi, Matthew, Eades, Benjamin M, Swift, Regina A, Schwartz, Gary, Eshaghian, Shahrooz, Stampleman, Laura, Moss, Robert A, Lim, Stephen, Vescio, Robert

“…Ruxolitinib with lenalidomide and dexamethasone shows antimyeloma effects and . MUC1 leads to lenalidomide resistance in multiple myeloma cells, and…”
Get full text

A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma by Yashar, David, Spektor, Tanya M., Martinez, Daisy, Ghermezi, Matthew, Swift, Regina A., Eades, Benjamin, Schwartz, Gary, Eshaghian, Shahrooz, Lim, Stephen, Vescio, Robert, Berenson, James R.

“…High-risk multiple myeloma (MM) continues to have a poor prognosis and remains a therapeutic challenge. This phase 2 study evaluated the efficacy and safety of…”
Get full text

Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen by Afari, Jonathan, Spektor, Tanya M., Turner, Carley, Cohen, Alexa, Bessudo, Alberto, Jhangiani, Haresh, Gabrail, Nashat, Kubba, Samir, Neidhart, Jeffrey D., Eshaghian, Shahrooz, Swift, Regina A., Eades, Benjamin M., Kim, Clara, Kim, Susanna, Vescio, Robert, Berenson, James R.

“…•Pomalidomide is possibly a replacement drug for myeloma patients refractory to lenalidomide.•Pomalidomide achieves responses among myeloma patients refractory…”
Get full text

A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen by Daniely, David, Forouzan, Eli, Spektor, Tanya M., Cohen, Alexa, Bitran, Jacob D., Chen, Gigi, Moezi, Mehdi M., Bessudo, Alberto, Hrom, John, Eshaghian, Shahrooz, Swift, Regina A., Eades, Benjamin M., Kim, Clara, Lim, Stephen, Berenson, James R.

“…•Replacement of bortezomib or carfilzomib with ixazomib in RRMM was investigated•Patients continued use of the same drugs, dose, and frequency of non-PI…”
Get full text

A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients by Berenson, James R., Kim, Clara, Bujarski, Sean, To, Jennifer, Spektor, Tanya M., Martinez, Daisy, Turner, Carley, Ghermezi, Matthew, Eades, Benjamin M., Swift, Regina A., Schwartz, Gary, Eshaghian, Shahrooz, Moss, Robert A., Lim, Stephen, Vescio, Robert

“…Ruxolitinib with lenalidomide and dexamethasone shows anti‐myeloma effects in vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma (MM)…”
Get full text

Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy by Wang, James, Udd, Kyle A., Vidisheva, Aleksandra, Swift, Regina A., Spektor, Tanya M., Bravin, Eric, Ibrahim, Emad, Treisman, Jonathan, Masri, Mohammed, Berenson, James R.

“…Purpose Previous studies have shown that low serum vitamin D levels have been associated with many skeletal and non-skeletal disorders. We studied the…”
Get full text

Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma by Bujarski, Sean, Goldwater, Marissa‐Skye, Regidor, Bernard Sean, Jew, Scott, Daniely, David, Swift, Regina A., Eades, Benjamin M., Emamy‐Sadr, Marsiye, Souther, Eric, Li, Mingjie, Wang, Cathy, Xu, Ning, Chen, Haiming, Spektor, Tanya M., Berenson, James R.

“…Multiple myeloma (MM) patients with smoldering (S) disease are defined by a lack of CRAB/SLiM criteria but may transform into disease requiring treatment. The…”
Get full text

Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone by Bujarski, Sean, Sutanto, Christine, Spektor, Tanya M., To, Jennifer, Swift, Regina A., Green, Tracy, Eades, Benjamin R., Emamy‐Sadr, Marsiye, Souther, Eric, Berenson, James R.

“…Previous retrospective studies have shown that serum B‐cell maturation antigen (sBCMA) levels predict outcomes among patients with multiple myeloma (MM)…”
Get full text

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma by Cohen, Alexa, Spektor, Tanya M., Stampleman, Laura, Bessudo, Alberto, Rosen, Peter J., Klein, Leonard M., Woliver, Thomas, Flam, Marshall, Eshaghian, Shahrooz, Nassir, Youram, Maluso, Tina, Swift, Regina A., Vescio, Robert, Berenson, James R.

“…Summary Immunomodulatory drugs including thalidomide, lenalidomide (LEN) and pomalidomide (POM), are effective for treating multiple myeloma (MM). POM has…”
Get full text

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma by Berenson, James R., Yellin, Ori, Bessudo, Alberto, Boccia, Ralph V., Noga, Stephen J., Gravenor, Donald S., Patel‐Donnelly, Dipti, Siegel, Robert S., Kewalramani, Tarun, Gorak, Edward J., Nassir, Youram, Swift, Regina A., Mayo, Debra

“…Summary Bendamustine, active in multiple myeloma (MM), is a bifunctional mechlorethamine derivative with alkylating properties. Bortezomib, approved to treat…”
Get full text

A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma by Berenson, James R., Yellin, Ori, Shamasunder, Hesaraghatta K., Chen, Chien-Shing, Charu, Veena, Woliver, Thomas B., Sanani, Shamel, Schlutz, Michael, Nassir, Youram, Swift, Regina A., Andreu-Vieyra, Claudia, Vescio, Robert

“…Purpose Fatigue is a common problem among multiple myeloma (MM) patients. Armodafinil is a drug known to promote wakefulness, which is related to modafinil, a…”
Get full text

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma by Berenson, James R., Hilger, James D., Yellin, Ori, Boccia, Ralph V., Matous, Jeffrey, Dressler, Kenneth, Ghazal, Hassan H., Jamshed, Saad, Kingsley, Edwin C., Harb, Wael A., Noga, Stephen J., Nassir, Youram, Swift, Regina A., Vescio, Robert

“…Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with other agents, recently…”
Get full text

Risk of skin cancer in multiple myeloma patients: a retrospective cohort study by Robinson, Austin A., Wang, James, Vardanyan, Suzie, Madden, Erik K., Hebroni, Frank, Udd, Kyle A., Spektor, Tanya M., Nosrati, Jason D., Kitto, Alex Z., Zahab, Michael, Cheema, Simrin, Fors, Darron H., Norberg, Adam, Diehl, Joseph, Waterman, Gabriel N., Swift, Regina A., Crowley, John, Berenson, James R.

“…Immunosuppressed patients are known to have an increased incidence of skin cancer. Patients with multiple myeloma (MM) show impaired immune function. In the…”
Get full text

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment by Vidisheva, Aleksandra P., Wang, James, Spektor, Tanya M., Bitran, Jacob D, Lutzky, Jose, Tabbara, Imad A., Ye, Joseph Z., Ailawadhi, Sikander, Stampleman, Laura V., Steis, Ronald G., Moezi, Mehdi M., Swift, Regina A., Maluso, Tina M, Udd, Kyle A, Eshaghian, Shahrooz, Nassir, Youram, Berenson, James R.

“…Objective Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on…”
Get full text

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients by Berenson, James R., Yellin, Ori, Chen, Chien‐Shing, Patel, Ravi, Bessudo, Alberto, Boccia, Ralph V., Yang, Hank H., Vescio, Robert, Yung, Elizabeth, Mapes, Russell, Eades, Benjamin, Hilger, James D., Wirtschafter, Eric, Hilger, Jacqueline, Nassir, Youram, Swift, Regina A.

“…Summary The combination of pegylated liposomal doxorubicin (PLD), bortezomib and dexamethasone has shown efficacy in the treatment of multiple myeloma (MM)…”
Get full text